Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.39 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 3/20 | 0.39 |
| ▸ | MYC | P01106 | 1/20 | 0.38 |
| ▸ | MAX | P61244 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | GUSB | P08236 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30612099 | 0.81 | MAPT (0.47) | MAPTGAAENPP3ENPP1SMN1; SMN2 | |
| SCHEMBL5249809 | 0.81 | MAPT (0.57) | MAPTGAAENPP3ENPP1NQO2 | |
| SCHEMBL26103062 | 0.81 | MAPT (0.47) | MAPTGAAENPP3ENPP1SMN1; SMN2 | |
| SCHEMBL31347015 | 0.79 | MAPT (0.39) | MAPTGAAENPP3ENPP1NQO2 | |
| SCHEMBL26107319 | 0.79 | MAPT (0.39) | MAPTGAAENPP3ENPP1NQO2 | |
| SCHEMBL31327745 | 0.78 | ENPP3 (0.48) | MAPTGAAENPP3ENPP1NQO2 | |
| SCHEMBL28858276 | 0.78 | ENPP3 (0.48) | MAPTGAAENPP3ENPP1NQO2 | |
| SCHEMBL31266885 | 0.78 | KDM4E (0.54) | SMN1; SMN2MEN1KMT2AKDM4EHTT | |
| SCHEMBL28479641 | 0.78 | MAPT (0.44) | MAPTGAAENPP3ENPP1NQO2 | |
| SCHEMBL3631562 | 0.78 | CCR6 (0.44) | MAPTGAASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160314-A1 | Small Molecule Inhibitors of Toll-Like Receptor 9 | LIPFORD GRAYSON B | 2010-06-24 | — | — | US | disclosed |
| US-7598382-B2 | Aryl substituted imidazoquinolines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| EP-2081924-A2 | SMALL MOLECULE INHIBITORS OF TOLL-LIKE RECEPTOR 9 | Coley Pharmaceutical Group, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008030455-A2 | SMALL MOLECULE INHIBITORS OF TOLL-LIKE RECEPTOR 9 | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| US-7153865-B2 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2006-12-26 | — | — | US | disclosed |
| US-7091214-B2 | Aryl substituted Imidazoquinolines | 3M INNOVATIVE PROPERTIES CO. (US) | 2006-08-15 | — | — | US | disclosed |
| US-7060834-B2 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2006-06-13 | — | — | US | disclosed |
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY | 2006-05-25 | — | — | US | disclosed |
| EP-1590348-A1 | ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2005-11-02 | — | — | EP | disclosed |
| US-20050131020-A1 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2005-06-16 | — | — | US | disclosed |
| EP-1430030-B1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2005-05-18 | — | — | EP | disclosed |
| US-20040266819-A1 | N-type calcium channel antagonists for the treatment of pain | ASTRAZENECA AB (SE) | 2004-12-30 | — | — | US | disclosed |
| US-20040147543-A1 | Aryl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-29 | — | — | US | disclosed |
| WO-2004058759-A1 | ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-07-15 | — | — | WO | disclosed |
| EP-1430030-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2004-06-23 | — | — | EP | disclosed |
| EP-1430029-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003018561-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | disclosed |
| WO-2003018560-A1 | N-TYPE CALCIUM CHANNEL ANTAGONISTS FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266819-A1 | N-type calcium channel antagonists for the treatment of pain | CACNA1E, CACNA1B, CACNA1G | MAPT 2685/4885GAA 3720/4885ENPP3 2054/4885 |
| US-20050131020-A1 | N-type calcium channel antagonists for the treatment of pain | CACNA1E, CACNA1B, CACNA1A | MAPT 2489/4885GAA 4454/4885ENPP3 1821/4885 |
| US-20040147543-A1 | Aryl substituted imidazoquinolines | IL2, IFNG, IRF3 | MAPT 4429/4885GAA 1193/4885ENPP3 1775/4885 |
| US-20100160314-A1 | Small Molecule Inhibitors of Toll-Like Receptor 9 | TLR9, TLR3, TLR1 | MAPT 3558/4885GAA 3505/4885ENPP3 1740/4885 |
| US-20060111387-A1 | ARYL SUBSTITUTED IMIDAZOQUINOLINES | IL2, IFNG, IRF3 | MAPT 4429/4885GAA 1193/4885ENPP3 1775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.